Boehringer Ingelheim has announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on 29 May–2 June 2, 2015. A total of nine abstracts, including new data for afatinib and nintedanib, will emphasize the growing presence of Boehringer Ingelheim in lung and other cancer types.
The LUX-Lung 8 Phase III trial directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. The study met its primary endpoint of progression-free survival, as well as its key secondary endpoint of overall survival (OS). Overall safety findings for afatinib were consistent with previous reports. The OS data will be unveiled in an oral presentation on Sunday 13 May from 8:24 - 8:36 a.m. in N Hall B1. The outcome of the trial is highly anticipated due to the current poor prognosis and high level of unmet need for patients with this specific type of lung cancer.
"Boehringer Ingelheim is proud to present the overall survival results from the LUX-Lung 8 trial as well as data on other investigational compounds from our growing oncology pipeline," said Tunde Otulana, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Our ongoing research program with Gilotrif and other compounds underscores our commitment to advancing the care of people affected by cancer, particularly lung cancer."
